Divis Laboratories Ltd

Large Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Divis Laboratories shares experienced a 0.83% increase, reaching ₹6,138. Analysts recommend buying at ₹6,087 with a target of ₹6,850, citing strong growth strategies.

Divis Laboratories Sees Price Rise and Strong Recommendations - 02 May, 2025

Citigroup has assigned a buy rating to Divis Laboratories with a target price of Rs 7,050. Analysts highlight the company's potential as a primary supplier due to capacity expansion and the upcoming addition of Orforglipron in its pipeline. The stock is considered a top pick in the pharma sector.

Citigroup Initiates Buy Rating on Divis Laboratories - 25 Apr, 2025

Divis Laboratories saw significant stock gains after Citi raised its price target to ₹7,050, highlighting strong growth potential in GLP-1 products. Despite some caution from analysts, the overall sentiment remains positive as the company expands its capacity and product pipeline.

Divis Laboratories Gains on Positive Brokerage Ratings - 24 Apr, 2025

Divis Laboratories has entered a long-term manufacturing and supply agreement with a global pharmaceutical company, focusing on advanced intermediates. The company plans to invest ₹650-700 crore for capacity expansion, expecting significant revenue contributions from this partnership.

Divis Labs Secures Long-Term Pharma Supply Agreement - 18 Apr, 2025

Divis Laboratories shares fell over 6% to ₹5,410.60 following U.S. President Trump's comments on potential tariffs on pharmaceutical imports, raising investor concerns. The stock's decline reflects fears of increased manufacturing costs and policy risks for companies exporting to the U.S.

Divis Laboratories Shares Drop Amid Tariff Concerns - 04 Apr, 2025

Divis Laboratories shares saw a 1.90% increase following tariff exemptions for pharmaceuticals. SBI Securities recommends buying with targets of Rs 5,830 and Rs 5,900.

Divis Laboratories Shares Rise on Positive Recommendations - 03 Apr, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

In the last 1 year, DIVISLAB has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 1 year.

Best in 1 Year

In the last 7 days, DIVISLAB stock has moved up by 1.3%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Mutual Funds have increased holdings from 11.89% to 12.83% in Mar 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

Netprofit is up for the last 3 quarters, 430.0 Cr → 589.0 Cr (in ₹), with an average increase of 14.6% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Foreign Institutions have increased holdings from 17.99% to 18.01% in Mar 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Up

Promoters holdings remained unchanged at 51.89% of holdings in Mar 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 3 years, Torrent Pharmaceuticals Ltd has given 141.8% return, outperforming this stock by 101.3%

This section gives you an insight into how the peers have performed as compared to this company in the last 3 years.

Against Peers

Revenue is down for the last 2 quarters, 2.44K Cr → 2.40K Cr (in ₹), with an average decrease of 1.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Fall

Retail Investor have decreased holdings from 9.59% to 9.39% in Mar 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Nifty100 Quality

BSE Healthcare

BSE 100

S&P BSE 250 LargeMidCap

S&P BSE 100 LargeCap TMC

NIFTY 100

Nifty Next 50

Nifty 200

S&P BSE SEN. N50

BSE 200

S&P BSE Largecap

Nifty Healthcare

S&P BSE Momentum

Nifty Alpha 50

BSE MFG

NIFTY PHARMA

Nifty100 Eq Weig

Nifty LargeMidcap 250

S&P BSE Dividend Stability

Nifty 500

BSE 500

SBI Equity Hybrid Fund Direct Growth

SBI Bluechip Fund Direct Growth

SBI Focused Equity Fund Direct Plan Growth

Axis ELSS Tax Saver Fund Direct Plan Growth Option

Nippon India Pharma Fund - Direct Plan - Growth Plan

Divis Laboratories Ltd’s net profit jumped 64.53% since last year same period to ₹589Cr in the Q3 2024-2025. On a quarterly growth basis, Divis Laboratories Ltd has generated 15.49% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	-1.63	Bearish
CCI (20)	-83.63	Neutral
RSI (14)	42.96	Neutral
Momentum (10)	-9.5	Bearish
ADI (14)	17.36	Neutral
Ultimate Oscillator (7,14,28)	52.52	Neutral

Name	Value	Action
SMA (20)	6103.02	Bearish
EMA (20)	6102.04	Bearish
VWMA (20)	6101.3	Bearish
SMA (50)	6102.19	Bearish
EMA (50)	6101.54	Bearish
SMA (200)	6084.61	Bullish
EMA (200)	6092.4	Bullish
KAMA (200)	6096.68	Bullish
DEMA (200)	6097.01	Bearish

Divis Laboratories Ltd (DIVISLAB)

Summary

Overall

Oscillators

Moving Averages